Research programme: cancer therapeutics - AstraZeneca

Drug Profile

Research programme: cancer therapeutics - AstraZeneca

Alternative Names: AZ-32; AZ-82

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Radiosensitisers; Small molecules
  • Mechanism of Action Ataxia telangiectasia mutated protein inhibitors; KIFC1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glioblastoma
  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Cancer in USA
  • 16 Apr 2016 Pharmacokinetics data from a preclinical trial in Glioblastoma presented at the107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 01 Apr 2016 Preclinical trials in Glioblastoma in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top